Genentech is teaming with Seattle’s Adaptive Biotechnologies to develop cancer immunotherapies specific to individual patients. The latter uses scanning technology that can search the immune system for targets for cell therapies. Adaptive will check its library of T-cell receptors found by the tech to identify ones useful in therapies, which Genentech will then engineer and manufacture as part of the $300bn partnership. In a statement, Gene Therapeutics said it was “excited about this partnership because we believe our approach has great potential to help patients who are suffering from cancer”. The San Francisco-based group will also deal with clinical testing, commercialisation and regulatory work. Genentech, the San Francisco-based subsidiary of pharmaceutical giant Roche, could pay Adaptive $2 billion or more in milestones as the experimental therapies in the partnership progress. Adaptive will receive royalties from any therapies reaching market.
Genentech is teaming with Seattle’s Adaptive Biotechnologies to develop cancer immunotherapies specific to individual patients. The latter uses scanning technology that can search the immune system for targets for cell therapies. Adaptive will check its library of T-cell receptors found by the tech to identify ones useful in therapies, which Genentech will then engineer and manufacture as part of the $300bn partnership. In a statement, Gene Therapeutics said it was “excited about this partnership because we believe our approach has great potential to help patients who are suffering from cancer”. The San Francisco-based group will also deal with clinical testing, commercialisation and regulatory work. Adaptive will receive royalties from any therapies reaching market.